Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Next Previous
Search
Trial Profile

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lemzoparlimab (Primary) ; Pembrolizumab (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma; Bladder cancer; Carcinoma; Diffuse large B cell lymphoma; Fallopian tube cancer; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors AbbVie; I-MAB Biopharma

    • Most Recent Events

    • 28 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 22 Aug 2022 Status changed from recruiting to active, no longer recruiting.
    • 29 Mar 2022 According to an I-MAB Biopharma media release, the dose expansion trial is ongoing to enroll more patients in the U.S. and at additional clinical sites in China. The Company expects to report additional data in 2H2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top